Figure 1.
Time to first onset of herpes zoster during treatment with anifrolumab 300 mg versus placebo in pooled MUSE, TULIP-1 and TULIP-2 data. If a patient had no herpes zoster during treatment, the time to first onset was censored at the date of last administration of investigational product plus 28 days.